Skip to main content
. 2018 Oct;9(5):894–902. doi: 10.21037/jgo.2018.04.09

Table 2. Univariate analysis comparing leak rates of upfront surgery vs. neoadjuvant therapy.

Variable Non-PSM PSM
Surgery/neoadjuvant leak (%) OR* 95% CI P Surgery/neoadjuvant leak (%) OR* 95% CI P
Overall 8.0/4.1 0.50 0.27–0.91 0.02 7.7/4.2 0.53 0.25–1.13 0.14
Year
   1996–2000 10.0/2.0 0.19 0.02–1.55 0.12 8.2/2.5 0.29 0.03–2.47 0.25
   2001–2005 9.3/4.2 0.42 0.14–1.31 0.14 9.5/2.5 0.24 0.06–0.98 0.05
   2006–2010 5.8/5.6 0.96 0.32–2.85 0.94 6.3/6.9 1.11 0.33–3.79 0.87
   After 2010 9.7/2.8 0.27 0.06–1.27 0.1 9.5/8.3 0.86 0.07–10.66 0.91
Histology
   Adenocarcinoma 8.5/4.1 0.46 0.24–0.86 0.01 8.2/4.7 0.56 0.26–1.20 0.14
   Squamous cell 3.3/4.5 1.36 0.14–13.63 0.79 3.7/0
Location
   Middle 0/3.6 0/7.1
   Lower 5.9/5.0 0.85 0.36–2.01 0.71 4.8/3.0 0.61 0.19–1.98 0.41
   GEJ 12.7/3.7 0.26 0.10–0.72 0.01 13.8/6.7 0.44 0.15–1.31 0.14
Technique
   Open TH 16.7/11.8 0.67 0.16–2.75 0.57 13.8/7.4 0.50 0.08–2.98 0.45
   Open IVL 7.0/3.3 0.46 0.19–1.10 0.08 6.9/3.4 0.47 0.17–1.28 0.14
   Open 3F 0/25.0 0/66.7
   Lap TH 10.0/4.8 0.45 0.06–3.45 0.44 10.0/0
   Lap TT 0/5.6 0/5.0
   RAIL 10.7/0.9 0.08 0.01–0.78 0.03 14.3/0
Anastomosis
   Thoracic 6.8/3.1 0.44 0.21–0.91 0.03 6.8/3.4 0.49 0.19–1.23 0.13
   Cervical 13.0/9.8 0.73 0.25–2.13 0.56 11.5/7.4 0.61 0.16–2.31 0.47
Diabetes
   No 8.0/3.4 0.40 0.20–0.80 0.01 8.0/3.6 0.42 0.18–1.00 0.05
   Yes 8.1/8.0 0.99 0.24–4.06 0.99 5.7/8.6 1.55 0.24–9.88 0.64
BMI
   18.5–25 14.8/4.4 0.27 0.09–0.75 0.01 14.8/0
   25.1–30 5.3/1.8 0.33 0.08–1.41 0.13 5.3/3.2 0.59 0.14–2.53 0.47
   >30 5.8/7.2 1.27 0.44–3.68 0.66 5.8/7.7 1.36 0.45–4.07 0.58

*, surgery as reference. PSM, propensity score match; GEJ, gastroesophageal junction; TH, transhiatal; IVL, Ivor-Lewis; TT, transthoracic; RAIL, robotic assisted Ivor-Lewis; BMI, body mass index.